Paroxetine: an update of its use in psychiatric disorders in adults.

  title={Paroxetine: an update of its use in psychiatric disorders in adults.},
  author={Antona J. Wagstaff and Susan M. Cheer and Anna J. Matheson and Douglas J. Ormrod and Karen L. Goa},
  volume={62 4},
Paroxetine is a selective serotonin reuptake inhibitor (SSRI), with antidepressant and anxiolytic activity. In 6- to 24-week well designed trials, oral paroxetine 10 to 50 mg/day was significantly more effective than placebo, at least as effective as tricyclic antidepressants (TCAs) and as effective as other SSRIs and other antidepressants in the treatment of major depressive disorder. Relapse or recurrence over 1 year after the initial response was significantly lower with paroxetine 10 to 50… 

Paroxetine: current status in psychiatry

  • C. PaeA. Patkar
  • Psychology, Medicine
    Expert review of neurotherapeutics
  • 2007
The efficacy and tolerability data for paroxetine appears to be comparable with other SSRIs in the treatment of major depression, and it is approved for use in a wider variety of anxiety disorders than any other antidepressant.

Paroxetine: safety and tolerability issues

Whether the tolerability profile of paroxetine differs substantially from other new antidepressants (including other SSRIs) needs to be determined in adequately powered well-designed randomised controlled comparative clinical trials.

Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study

The results of this study suggest that slow paroxetine up-titration is better tolerated and at least as effective as the standard paroxete up-Titration in cancer patients with depression.

Paroxetine in the treatment of generalised anxiety disorder

Antidepressants, such as paroxetine, are more effective for the psychic symptoms of anxiety, which include worry, tension, irritability and concentration difficulties, and carry a more tolerable and safe side effect profile.

Paroxetine Controlled Release

In well designed placebo-controlled trials in patients with major depressive disorder, social anxiety disorder or premenstrual dysphoric disorder, paroxetine CR was consistently superior to placebo with regards to primary endpoints.

An evaluation of paroxetine in generalised social anxiety disorder

The pharmacotherapy of social phobia will be reviewed, with a special focus on investigations with paroxetine, the most studied agent in social anxiety disorder.

Paroxetine for the treatment of depression: a critical update

The pharmacokinetic and pharmacodynamic properties of the molecule are fundamental to guiding its prescription, both for efficacy and tolerability issues, for example, it can have a high impact on sexual function and weight should be considered at the beginning of treatment.

Evaluation of Clinical Response According to Plasma Paroxetine Level in Paroxetine-Responsive Major Depression

Higher PPL levels in the third week suggested that PPL measurement may be more reliable in the 3rd week than the first week, and suggested that there is a large amount of interpersonal pharmacogenetic variability for paroxetine metabolism.

Effectiveness of paroxetine in the treatment of poststroke depression

It is indicated that paroxetine may not bring promising effectiveness for patients with PSD, and future studies are still needed to warrant the results of this study.



Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

The good tolerability profile of paroxetine, including lack of dependence potential and relative safety in overdose, makes it attractive for the treatment of patients with panic disorder and it appears to be at least as effective as clomipramine in reducing panic attacks and associated symptoms.

Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.

Long term data suggest that paroxetine is effective and well tolerated, and suitable as first-line therapy for depression, and also appears to be a useful alternative to other available agents for the treatment of patients with OCD or panic disorder.

Fluoxetine : A review of its use in anxiety disorders and mixed anxiety and depression

Fluoxetine is effective in the short term treatment of panic, social anxiety, post-traumatic stress and obsessive-compulsive disorders, and may be effective in patients experiencing anxiety symptoms and depression.

A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.

Paroxetine in the treatment of depression

Both drugs were well tolerated with nausea and headache in four patients and somnolence in six patients being reported as the most common side‐effect for paroxetine and mianserin respectively.

Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study.

The authors proposed that the more rapid improvement demonstrated by the group receiving the combination of lithium and paroxetine may be due to the synergistic serotonergic effects of these two medications.

A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.

Observed differences in some side effects, although not statistically significant, indicate that when a patient has difficulty tolerating one SSRI, the clinician may choose to change to a different agent within the same class.

Controlled comparison of paroxetine and fluvoxamine in major depression

A multicentre study compared the antidepressant efficacy and the tolerance of two selective serotonin reuptake inhibitors, paroxetine (20–30 mg/d) and fluvoxamine (50–200 mg/d) in two parallel groups

Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double blind, parallel group study.

Paroxetine was as effective as amitriptyline for the treatment of depression, with similar improvements in RA associated pain and disability also seen in both groups, however, paroxETine was better tolerated than amitripyline.

Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study.

The data suggest that a full dose of paroxetine is recommended in unipolar patients who are at high risk for recurrent depressive episodes, and a randomized, double-blind, parallel-group study is recommended.